Статья
Нарушения липидного обмена при метаболическом синдроме
В статье проанализированы современные представления о патогенезе, диагностике и влиянии на прогноз нарушений липидного обмена при метаболическом синдроме. Приведен обзор современных возможностей диагностики, немедикаментозной и медикаментозной терапии нарушений липидного обмена при метаболическом синдроме, особое внимание уделено вопросам метаболических эффектов гиполипидемической терапии.
1. Pan WH, Yeh WT, Weng LC. Epidemiology of metabolic syndrome in Asia. Asia Pac J Clin Nutr. 2008;17 Suppl 1:37-42.
2. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709-16. doi:10.1001/jama.288.21.2709.
3. Choi SH, Ginsberg HN. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab. 2011;22(9):353-63. doi:10.1016/j.tem.2011.04.007.
4. Adiels M, Olofsson SO, Taskinen MR, et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(7):1225-36. doi:10.1161/ATVBAHA.107.160192.
5. Bergman RN, Kim SP, Hsu IR, et al. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med. 2007;120(2 Suppl 1):S3-8; discussion S29-32. doi:10.1016/j.amjmed.2006.11.012.
6. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148(5):852-71. doi:10.1016/j.cell.2012.02.017.
7. Kissebah AH, Alfarsi S, Evans DJ, et al. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes. 1982;31(3):217-25. doi:10.2337/diab.31.3.217.
8. Duvillard L, Pont F, Florentin E, et al. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest. 2000;30(8):685-94.
9. Lewis GF, Uffelman KD, Szeto LW, et al. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest. 1995;95(1):158-66. doi:10.1172/JCI117633.
10. Boquist S, Hamsten A, Karpe F, et al. Insulin and non-esterified fatty acid relations to alimentary lipaemia and plasma concentrations of postprandial triglyceride-rich lipoproteins in healthy middle-aged men. Diabetologia. 2000;43(2):185-93. doi:10.1007/s001250050028.
11. Fabbrini E, Mohammed BS, Magkos F, et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 2008;134(2):424-31. doi:10.1053/j.gastro.2007.11.038.
12. Costabile G, Annuzzi G, Di Marino L, et al. Fasting and post-prandial adipose tissue lipoprotein lipase and hormone-sensitive lipase in obesity and type 2 diabetes. J Endocrinol Invest. 2011;34(5):e110-4. doi:10.1007/BF03347469.
13. Diraison F, Moulin P, Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab. 2003;29(5):478-85. doi:10.1016/s1262-3636(07)70061-7.
14. Ameer F, Scandiuzzi L, Hasnain S, et al. De novo lipogenesis in health and disease. Metabolism. 2014;63(7):895-902. doi:10.1016/j.metabol.2014.04.003.
15. Onyango AN. Excessive gluconeogenesis causes the hepatic insulin resistance paradox and its sequelae. Heliyon. 2022;8(12):e12294. doi:10.1016/j.heliyon.2022.e12294.
16. Tobin KA, Ulven SM, Schuster GU, et al. Liver X receptors as insulin-mediating factors in fatty acid and cholesterol biosynthesis. J Biol Chem. 2002;277(12):10691-7. doi:10.1074/jbc.M109771200.
17. Cha JY, Repa JJ. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem. 2007;282(1):743-51. doi:10.1074/jbc.M605023200.
18. Higuchi N, Kato M, Shundo Y, et al. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol Res. 2008;38(11):1122-9. doi:10.1111/j.1872-034X.2008.00382.x.
19. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125-31. doi:10.1172/JCI15593.
20. Hegarty BD, Bobard A, Hainault I, et al. Distinct roles of insulin and liver X receptor in the induction and cleavage of sterol regulatory element-binding protein-1c. Proc Natl Acad Sci U S A. 2005;102(3):791-6. doi:10.1073/pnas.0405067102.
21. Wetterau JR, Zilversmit DB. A triglyceride and cholesteryl ester transfer protein associated with liver microsomes. J Biol Chem. 1984;259(17):10863-6.
22. Iqbal J, Jahangir Z, Al-Qarni AA. Microsomal Triglyceride Transfer Protein: From Lipid Metabolism to Metabolic Diseases. Adv Exp Med Biol. 2020;1276:37-52. doi:10.1007/978-981-15-6082-8_4.
23. Wetterau JR, Aggerbeck LP, Bouma ME, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science. 1992;258(5084):999-1001. doi:10.1126/science.1439810.
24. Raabe M, Véniant MM, Sullivan MA, et al. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J Clin Invest. 1999;103(9):1287-98. doi:10.1172/JCI6576.
25. Jamil H, Dickson JK Jr, Chu CH, et al. Microsomal triglyceride transfer protein. Specificity of lipid binding and transport. J Biol Chem. 1995;270(12):6549-54. doi:10.1074/jbc.270.12.6549.
26. Patel SB, Grundy SM. Interactions between microsomal triglyceride transfer protein and apolipoprotein B within the endoplasmic reticulum in a heterologous expression system. J Biol Chem. 1996;271(31):18686-94. doi:10.1074/jbc.271.31.18686.
27. Kamagate A, Qu S, Perdomo G, et al. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest. 2008;118(6):2347-64. doi:10.1172/JCI32914.
28. Haas ME, Attie AD, Biddinger SB. The regulation of ApoB metabolism by insulin. Trends Endocrinol Metab. 2013;24(8):391-7. doi:10.1016/j.tem.2013.04.001.
29. Yao Z. Human apolipoprotein C-III — a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteins. Cardiovasc Hematol Disord Drug Targets. 2012;12(2):133-40. doi:10.2174/1871529x11202020133.
30. Chamberlain JM, O’Dell C, Sparks CE, et al. Insulin suppression of apolipoprotein B in McArdle RH7777 cells involves increased sortilin 1 interaction and lysosomal targeting. Biochem Biophys Res Commun. 2013;430(1):66-71. doi:10.1016/j.bbrc.2012.11.022.
31. Mazzone T, Foster D, Chait A. In vivo stimulation of low-density lipoprotein degradation by insulin. Diabetes. 1984;33(4):333-8. doi:10.2337/diab.33.4.333.
32. Howard BV, Abbott WG, Beltz WF, et al. Integrated study of low density lipoprotein metabolism and very low density lipoprotein metabolism in non-insulin-dependent diabetes. Metabolism. 1987;36(9):870-7. doi:10.1016/0026-0495(87)90096-5.
33. Wade DP, Knight BL, Soutar AK. Regulation of low-density-lipoprotein-receptor mRNA by insulin in human hepatoma Hep G2 cells. Eur J Biochem. 1989;181(3):727-31. doi:10.1111/j.1432-1033.1989.tb14784.x.
34. Go GW, Mani A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J Biol Med. 2012;85(1):19-28.
35. Rakipovski G, Hovingh GK, Nyberg M. Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin? Curr Opin Lipidol. 2020;31(6):340-6. doi:10.1097/MOL.0000000000000718.
36. Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009;94(7):2537-43. doi:10.1210/jc.2009-0141.
37. Duvillard L, Florentin E, Lizard G, et al. Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy. Diabetes Care. 2003;26(5):1540-4. doi:10.2337/diacare.26.5.1540.
38. Kohan AB. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2015;22(2):119-25. doi:10.1097/MED.0000000000000136.
39. Larsson M, Vorrsjö E, Talmud P, et al. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J Biol Chem. 2013;288(47):33997-4008. doi:10.1074/jbc.M113.495366.
40. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 1991;266(27):18259-67.
41. Altomonte J, Cong L, Harbaran S, et al. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest. 2004;114(10):1493-503. doi:10.1172/JCI19992.
42. Caron S, Verrijken A, Mertens I, et al. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2011;31(3):513-9. doi:10.1161/ATVBAHA.110.220723.
43. Chan DC, Watts GF, Barrett PH, et al. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem. 2002;48(2):278-83.
44. Kobayashi J, Miyashita K, Nakajima K, et al. Hepatic Lipase: a Comprehensive View of its Role on Plasma Lipid and Lipoprotein Metabolism. J Atheroscler Thromb. 2015;22(10):1001-11. doi:10.5551/jat.31617.
45. Carr MC, Hokanson JE, Zambon A, et al. The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity. J Clin Endocrinol Metab. 2001;86(6):2831-7. doi:10.1210/jcem.86.6.7586.
46. Toth PP. Insulin resistance, small LDL particles, and risk for atherosclerotic disease. Curr Vasc Pharmacol. 2014;12(4):653-7. doi:10.2174/15701611113119990125.
47. Xepapadaki E, Nikdima I, Sagiadinou EC, et al. HDL and type 2 diabetes: the chicken or the egg? Diabetologia. 2021;64(9):1917-26. doi:10.1007/s00125-021-05509-0.
48. Dullaart RP, Sluiter WJ, Dikkeschei LD, et al. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest. 1994;24(3):188-94. doi:10.1111/j.1365-2362.1994.tb00987.x.
49. Toh SA, Rader DJ. Dyslipidemia in insulin resistance: clinical challenges and adipocentric therapeutic frontiers. Expert Rev Cardiovasc Ther. 2008;6(7):1007-22. doi:10.1586/14779072.6.7.1007.
50. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2001;21(1):13-27. doi:10.1161/01.atv.21.1.13.
51. Rashid S, Watanabe T, Sakaue T, et al. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003;36(6):421-9. doi:10.1016/s0009-9120(03)00078-x.
52. Thuren T. Hepatic lipase and HDL metabolism. Curr Opin Lipidol. 2000;11(3):277-83. doi:10.1097/00041433-200006000-00008.
53. Horowitz BS, Goldberg IJ, Merab J, et al. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest. 1993;91(4):1743-52. doi:10.1172/JCI116384.
54. Badellino KO, Wolfe ML, Reilly MP, et al. Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med. 2006;3(2):e22. doi:10.1371/journal.pmed.0030022.
55. Knapp M, Gorski J. Endothelial lipase: regulation and biological function. J Physiol Pharmacol. 2022;73(3). doi:10.26402/jpp.2022.3.01.
56. Ishida T, Choi S, Kundu RK, et al. Endothelial lipase is a major determinant of HDL level. J Clin Invest. 2003;111(3):347-55. doi:10.1172/JCI16306.
57. Maugeais C, Tietge UJ, Broedl UC, et al. Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase. Circulation. 2003;108(17):2121-6. doi:10.1161/01.CIR.0000092889.24713.DC.
58. Jin W, Millar JS, Broedl U, et al. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest. 2003;111(3):357-62. doi:10.1172/JCI16146.
59. Edmondson AC, Brown RJ, Kathiresan S, et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest. 2009;119(4):1042-50. doi:10.1172/JCI37176.
60. Shiu SW, Tan KC, Huang Y, et al. Type 2 diabetes mellitus and endothelial lipase. Atherosclerosis. 2008;198(2):441-7. doi:10.1016/j.atherosclerosis.2008.03.012.
61. Klobučar I, Stadler JT, Klobučar L, et al. Associations between Endothelial Lipase, High-Density Lipoprotein, and Endothelial Function Differ in Healthy Volunteers and Metabolic Syndrome Patients. Int J Mol Sci. 2023;24(3):2073. doi:10.3390/ijms24032073.
62. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17(11):1410-22. doi:10.1038/nm.2538.
63. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72. doi:10.1093/eurheartj/ehx144.
64. Bentzon JF, Otsuka F, Virmani R, et al. Mechanisms of plaque formation and rupture. Circ Res. 2014;114(12):1852-66. doi:10.1161/CIRCRESAHA.114.302721.
65. Ikezaki H, Lim E, Cupples LA, et al. Small Dense Low-Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study. J Am Heart Assoc. 2021;10(5):e019140. doi:10.1161/JAHA.120.019140.
66. Vekic J, Zeljkovic A, Cicero AFG, et al. Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL. Medicina (Kaunas). 2022;58(2):299. doi:10.3390/medicina58020299.
67. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014; 384(9943):626-35. doi:10.1016/S0140-6736(14)61177-6.
68. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299-308. doi:10.1001/jama.298.3.299.
69. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298(3):309-16. doi:10.1001/jama.298.3.309.
70. Varbo A, Benn M, Tybjærg-Hansen A, et al. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128(12):1298-309. doi:10.1161/CIRCULATIONAHA.113.003008.
71. Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524-33. doi:10.1038/s41586-021-03392-8.
72. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707-14. doi:10.1016/0002-9343(77)90874-9.
73. Rosenson RS, Brewer HB Jr, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125(15):1905-19. doi:10.1161/CIRCULATIONAHA.111.066589.
74. Rosenson RS, Brewer HB Jr, Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016;13(1):48-60. doi:10.1038/nrcardio.2015.124.
75. Wu X, Yu Z, Su W, et al. Low levels of ApoA1 improve risk prediction of type 2 diabetes mellitus. J Clin Lipidol. 2017;11(2):362-8. doi:10.1016/j.jacl.2017.01.009.
76. Wu L, Parhofer KG. Diabetic dyslipidemia. Metabolism. 2014;63(12):1469-79. doi:10.1016/j.metabol.2014.08.010.
77. Drew BG, Duffy SJ, Formosa MF, et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation. 2009;119(15):2103-11. doi:10.1161/CIRCULATIONAHA.108.843219.
78. Kruit JK, Brunham LR, Verchere CB, et al. HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Curr Opin Lipidol. 2010;21(3):178-85. doi:10.1097/MOL.0b013e328339387b.
79. Сергиенко И. В., Курочкина Н. С., Прус Ю. А. и др. Гиполипидемическая терапия. М.: Национальный медицинский исследовательский центр кардиологии им. академика Е. И. Чазова, 2024. 47 с. ISBN: 978-5-93856-824-2.
80. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. doi:10.1016/j.atherosclerosis.2019.08.014.
81. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625.
82. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord. 1997;21 Suppl 1:S5-9.
83. Chan DC, Barrett PH, Watts GF. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. Best Pract Res Clin Endocrinol Metab. 2014;28(3):369-85. doi:10.1016/j.beem.2013.10.001.
84. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56(2):320-8. doi:10.1093/ajcn/56.2.320.
85. Siri-Tarino PW, Krauss RM. Diet, lipids, and cardiovascular disease. Curr Opin Lipidol. 2016;27(4):323-8. doi:10.1097/MOL.0000000000000310.
86. Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond). 2015;39(8):1188-96. doi:10.1038/ijo.2015.59.
87. Dietschy JM. Dietary fatty acids and the regulation of plasma low density lipoprotein cholesterol concentrations. J Nutr. 1998;128(2 Suppl):444S-448S. doi:10.1093/jn/128.2.444S.
88. Keys A, Aravanis C, Blackburn HW, et al. Epidemiological studies related to coronary heart disease: characteristics of men aged 40-59 in seven countries. Acta Med Scand Suppl. 1966;460:1-392.
89. Siri-Tarino PW, Chiu S, Bergeron N, et al. Saturated Fats Versus Polyunsaturated Fats Versus Carbohydrates for Cardiovascular Disease Prevention and Treatment. Annu Rev Nutr. 2015;35:517-43. doi:10.1146/annurev-nutr-071714-034449.
90. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb. 1992;12(8):911-9. doi:10.1161/01.atv.12.8.911.
91. Jakobsen MU, Dethlefsen C, Joensen AM, et al. Intake of carbohydrates compared with intake of saturated fatty acids and risk of myocardial infarction: importance of the glycemic index. Am J Clin Nutr. 2010;91(6):1764-8. doi:10.3945/ajcn.2009.29099.
92. Drouin-Chartier JP, Tremblay AJ, Lépine MC, et al. Substitution of dietary ω-6 polyunsaturated fatty acids for saturated fatty acids decreases LDL apolipoprotein B-100 production rate in men with dyslipidemia associated with insulin resistance: a randomized controlled trial. Am J Clin Nutr. 2018;107(1):26-34. doi:10.1093/ajcn/nqx013.
93. Te Morenga LA, Howatson AJ, Jones RM, et al. Dietary sugars and cardiometabolic risk: systematic review and meta-analyses of randomized controlled trials of the effects on blood pressure and lipids. Am J Clin Nutr. 2014;100(1):65-79. doi:10.3945/ajcn.113.081521.
94. Yang Q, Zhang Z, Gregg EW, et al. Added sugar intake and cardiovascular diseases mortality among US adults. JAMA Intern Med. 2014;174(4):516-24. doi:10.1001/jamainternmed.2013.13563.
95. Snetselaar LG, de Jesus JM, DeSilva DM, et al. Dietary Guidelines for Americans, 2020-2025: Understanding the Scientific Process, Guidelines, and Key Recommendations. Nutr Today. 2021;56(6):287-95. doi:10.1097/NT.0000000000000512.
96. Delgado-Lista J, Perez-Martinez P, Garcia-Rios A, et al. Mediterranean Diet and Cardiovascular Risk: Beyond Traditional Risk Factors. Crit Rev Food Sci Nutr. 2016;56(5):788-801. doi:10.1080/10408398.2012.726660.
97. Chiu S, Bergeron N, Williams PT, et al. Comparison of the DASH (Dietary Approaches to Stop Hypertension) diet and a higher-fat DASH diet on blood pressure and lipids and lipoproteins: a randomized controlled trial. Am J Clin Nutr. 2016;103(2):341-7. doi:10.3945/ajcn.115.123281.
98. Jenkins DJ, Chiavaroli L, Wong JM, et al. Adding monounsaturated fatty acids to a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. CMAJ. 2010;182(18):1961-7. doi:10.1503/cmaj.092128.
99. Schoeneck M, Iggman D. The effects of foods on LDL cholesterol levels: A systematic review of the accumulated evidence from systematic reviews and meta-analyses of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2021;31(5):1325-38. doi:10.1016/j.numecd.2020.12.032.
100. Kodama S, Tanaka S, Saito K, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med. 2007;167(10):999-1008. doi:10.1001/archinte.167.10.999.
101. Kelley GA, Kelley KS, Vu Tran Z. Aerobic exercise, lipids and lipoproteins in overweight and obese adults: a meta-analysis of randomized controlled trials. Int J Obes (Lond). 2005;29(8):881-93. doi:10.1038/sj.ijo.0802959.
102. Durstine JL, Grandjean PW, Cox CA, et al. Lipids, lipoproteins, and exercise. J Cardiopulm Rehabil. 2002;22(6):385-98. doi:10.1097/00008483-200211000-00002.
103. Gordon B, Chen S, Durstine JL. The effects of exercise training on the traditional lipid profile and beyond. Curr Sports Med Rep. 2014;13(4):253-9. doi:10.1249/JSR.0000000000000073.
104. Kelley GA, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Prev Med. 2009;48(1):9-19. doi:10.1016/j.ypmed.2008.10.010.
105. Pattyn N, Cornelissen VA, Eshghi SR, et al. The effect of exercise on the cardiovascular risk factors constituting the metabolic syndrome: a meta-analysis of controlled trials. Sports Med. 2013;43(2):121-33. doi:10.1007/s40279-012-0003-z.
106. Liang M, Pan Y, Zhong T, et al. Effects of aerobic, resistance, and combined exercise on metabolic syndrome parameters and cardiovascular risk factors: a systematic review and network meta-analysis. Rev Cardiovasc Med. 2021;22(4):1523-33. doi:10.31083/j.rcm2204156.
107. Barone Gibbs B, Hivert MF, Jerome GJ, et al. Physical Activity as a Critical Component of First-Line Treatment for Elevated Blood Pressure or Cholesterol: Who, What, and How?: A Scientific Statement From the American Heart Association. Hypertension. 2021; 78(2):e26-e37. doi:10.1161/HYP.0000000000000196.
108. Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5(4):378-87. doi:10.1111/j.1582-4934.2001.tb00172.x.
109. Fulcher J, O’Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397-405. doi:10.1016/S0140-6736(14)61368-4.
110. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415-27. doi:10.2147/VHRM.S33664.
111. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251-61. doi:10.1016/j.atherosclerosis.2012.02.016.
112. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97. doi:10.1056/NEJMoa1410489.
113. Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial. Circulation. 2019;140(12):992-1003. doi:10.1161/CIRCULATIONAHA.118.039415.
114. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-92. doi:10.1016/S0140-6736(11)60739-3.
115. Lee S, Cannon CP. Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events. Curr Cardiol Rep. 2018;20(7):55. doi:10.1007/s11886-018-0997-4.
116. Civeira F, Pedro-Botet J. Cost-effectiveness evaluation of the use of PCSK9 inhibitors. Endocrinol Diabetes Nutr (Engl Ed). 2021;68(6):369-71. doi:10.1016/j.endien.2021.05.003.
117. Islam MS, Sharif A, Kwan N, et al. Bile Acid Sequestrants for Hypercholesterolemia Treatment Using Sustainable Biopolymers: Recent Advances and Future Perspectives. Mol Pharm. 2022;19(5):1248-72. doi:10.1021/acs.molpharmaceut.2c00007.
118. Mazidi M, Rezaie P, Karimi E, et al. The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: A systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2017;227:850-7. doi:10.1016/j.ijcard.2016.10.011.
119. Alder M, Bavishi A, Zumpf K, et al. A Meta-Analysis Assessing Additional LDL-C Reduction from Addition of a Bile Acid Sequestrant to Statin Therapy. Am J Med. 2020;133(11):1322-7. doi:10.1016/j.amjmed.2020.03.056.
120. Aggarwal S, Loomba RS, Arora RR. Efficacy of colesevelam on lowering glycemia and lipids. J Cardiovasc Pharmacol. 2012;59(2):198-205. doi:10.1097/FJC.0b013e31823a109f.
121. Goldfine AB, Fonseca VA, Jones MR, et al. Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes. Horm Metab Res. 2010;42(1):23-30. doi:10.1055/s-0029-1241195.
122. Berberich AJ, Hegele RA. Lomitapide for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2017;18(12):1261-8. doi:10.1080/14656566.2017.1340941.
123. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381(9860):40-6. doi:10.1016/S0140-6736(12)61731-0.
124. Blom DJ, Averna MR, Meagher EA, et al. Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Circulation. 2017;136(3):332-5. doi:10.1161/CIRCULATIONAHA.117.028208.
125. Kim NH, Choi J, Kim YH, et al. Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: A propensity-matched cohort study. Diabetes Metab. 2023;49(3):101428. doi:10.1016/j.diabet.2023.101428.
126. Abourbih S, Filion KB, Joseph L, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med. 2009;122(10):962.e1-8. doi:10.1016/j.amjmed.2009.03.030.
127. Saha SA, Kizhakepunnur LG, Bahekar A, et al. The role of fibrates in the prevention of cardiovascular disease–a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J. 2007;154(5):943-53. doi:10.1016/j.ahj.2007.07.011.
128. Арутюнов Г. П., Драпкина О. М., Кобалава Ж. Д. и др. Концепция применения комбинированных препаратов с фиксированными дозировками в первичной и вторичной профилактике сердечно-сосудистых заболеваний. Меморандум экспертов Российского кардиологического общества, Российского общества профилактики неинфекционных заболеваний, Российского научного медицинского общества терапевтов, Российской ассоциации эндокринологов, Ассоциации клинических фармакологов, Евразийской ассоциации терапевтов, Российской ассоциации геронтологов и гериатров. Российский кардиологический журнал. 2024;29(9):6074. doi:10.15829/1560-4071-2024-6074.
129. Liu QK. Triglyceride-lowering and anti-inflammatory mechanisms of omega-3 polyunsaturated fatty acids for atherosclerotic cardiovascular risk reduction. J Clin Lipidol. 2021;15(4):556-68. doi:10.1016/j.jacl.2021.05.007.
130. Sezai A, Unosawa S, Taoka M, et al. Long-Term Comparison of Ethyl Icosapentate vs. Omega-3-Acid Ethyl in Patients With Cardiovascular Disease and Hypertriglyceridemia (DEFAT Trial). Circ J. 2019;83(6):1368-76. doi:10.1253/circj.CJ-18-0764.
131. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268-80. doi:10.1001/jama.2020.22258.
132. Sarnak MJ, Bloom R, Muntner P, et al. KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD. Am J Kidney Dis. 2015;65(3):354-66. doi:10.1053/j.ajkd.2014.10.005.
133. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245-55. doi:10.1016/s0735-1097(86)80293-5.
134. Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-67. doi:10.1056/NEJMoa1107579.
135. Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203-12. doi:10.1056/NEJMoa1300955.
136. Abdul-Rahman T, Bukhari SMA, Herrera EC, et al. Lipid Lowering Therapy: An Era Beyond Statins. Curr Probl Cardiol. 2022;47(12):101342. doi:10.1016/j.cpcardiol.2022.101342.
137. Ruscica M, Sirtori CR, Carugo S, et al. Bempedoic Acid: for Whom and When. Curr Atheroscler Rep. 2022;24(10):791-801. doi:10.1007/s11883-022-01054-2.
138. Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018;277:195-203. doi:10.1016/j.atherosclerosis.2018.06.002.
139. Banach M, Duell PB, Gotto AM Jr, et al. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA Cardiol. 2020;5(10):1124-35. doi:10.1001/jamacardio. 2020.2314.
140. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388(15):1353-64. doi:10.1056/NEJMoa2215024.
141. Frampton JE. Inclisiran: A Review in Hypercholesterolemia. Am J Cardiovasc Drugs. 2023;23(2):219-30. doi:10.1007/s40256-023-00568-7.
142. Khan SA, Naz A, Qamar Masood M, et al. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. Am J Cardiol. 2020;134:69-73. doi:10.1016/j.amjcard.2020.08.018.
143. Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11(2):109-19. doi:10.1016/S2213-8587(22)00353-9.
144. Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17(1):83. doi:10.1186/s12933-018-0728-6.
145. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22. doi:10.1056/NEJMoa1603827.
146. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-44. doi:10.1056/NEJMoa1607141.
147. Hermansen K, Bækdal TA, Düring M, et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab. 2013;15(11):1040-8. doi:10.1111/dom.12133.
148. Vergès B, Duvillard L, Pais de Barros JP, et al. Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression. Diabetes Care. 2021;44(4):1027-37. doi:10.2337/dc20-1843.
149. Rizzo M, Nikolic D, Patti AM, et al. GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis. 2018;1864(9 Pt B):2814-21. doi:10.1016/j.bbadis.2018.05.012.
150. Fonseca-Correa JI, Correa-Rotter R. Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Front Med (Lausanne). 2021;8:777861. doi:10.3389/fmed.2021.777861.
151. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28. doi:10.1056/NEJMoa1504720.
152. Filippas-Ntekouan S, Tsimihodimos V, Filippatos T, et al. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opin Drug Metab Toxicol. 2018;14(11):1113-21. doi:10.1080/17425255.2018.1541348.
153. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108-17. doi:10.1007/s00125-018-4670-7.
154. Kahl S, Gancheva S, Straßburger K, et al. Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial. Diabetes Care. 2020;43(2):298-305. doi:10.2337/dc19-0641.
155. Полякова О. А., Козгунова Л. Д., Остроумова О. Д. Метаболически ассоциированная жировая болезнь печени: роль адеметионина. Фарматека. 2023;30(1/2):54-62. doi:10.18565/pharmateca.2023.1-2.54-62.
156. Virukalpattigopalratnam MP, Singh T, Ravishankar AC. Heptral (ademetionine) in patients with intrahepatic cholestasis in chronic liver disease due to non-alcoholic liver disease: results of a multicentre observational study in India. J Indian Med Assoc. 2013;111(12): 856-9.
157. Mahyoub MA, Elhoumed M, Maqul AH, et al. Fatty infiltration of the pancreas: a systematic concept analysis. Front Med (Lausanne). 2023;10:1227188. doi:10.3389/fmed.2023.1227188.
158. Dominguez-Muñoz JE, Vujasinovic M, de la Iglesia D, et al. European guidelines for the diagnosis and treatment of pancreatic exocrine insufficiency: UEG, EPC, EDS, ESPEN, ESPGHAN, ESDO, and ESPCG evidence-based recommendations. United European Gastroenterol J. 2025;13(1):125-72. doi:10.1002/ueg2.12674.
159. Ежов М. В., Кухарчук В. В., Сергиенко И. В. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. doi:10.15829/1560-4071-2023-5471.
160. Кобалава Ж. Д., Конради А. О., Недогода С. В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6117. doi:10.15829/1560-4071-2024-6117. EDN: GUEWLU.
161. Piano MR, Marcus GM, Aycock DM, et al. Alcohol Use and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2025;152(1):e7-e21. doi:10.1161/CIR.0000000000001341.
162. Noto H, Goto A, Tsujimoto T, et al. Effect of calcium channel blockers on incidence of diabetes: a meta-analysis. Diabetes Metab Syndr Obes. 2013;6:257-61. doi:10.2147/DMSO.S49767.
163. Pepine CJ, Cooper-Dehoff RM. Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol. 2004;44(3):509-12. doi:10.1016/j.jacc.2004.03.071.
164. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. doi:10.1016/S0140-6736(05)67185-1.
165. Ueno S, Hamada T, Taniguchi S, et al. Effect of Antihypertensive Drugs on Uric Acid Metabolism in Patients with Hypertension: Cross-Sectional Cohort Study. Drug Res (Stuttg). 2016;66(12):628-32. doi:10.1055/s-0042-113183.
166. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И. И. Дедова, М. В. Шестаковой, О. Ю. Сухаревой. 12-й выпуск. М.; 2025.